Evaluation of electromyoghraphy guided botolenium toxin type A injection in treating chronic migraine in Babylon province

الملخص EN

BOTOX is the first and only FDA-approved preventive treatment for chronic migraine.

It's also the only treatment for people with chronic migraine.

Current migraine preventive therapies are often unsatisfactory because of their limited efficacy, adverse effects, and drug interactions., Migraines typically present with pulsing head pain, nausea, photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

The aim of this study to evaluate the benefit of Botox injection in patients presented with chronic migraine and to determine the efficacy and safety for this kind of treatment in Babylon province.

This was an interventional study of 37 subjects with a history of chronic migraine (28 female and the other 9 were male), The patients received botulinum toxin type A, 100 U into 21 intramuscular injections using a 0.5-inch-long needle EMG guided connected to the machine.

and for 3 months following injection, subjects kept daily diaries in which they recorded headache frequency, duration, severity, and the occurrence of associated symptoms.

The study were done during the period from January/ 2017 until July/2017.

There were significant differences in patients with chronic migraine before and after treatment , in which there is significant decrease in migraine attacks per month, with reduction severity of these attacks, a significant decrease of hours in each attack and reduced incidence of migraine-associated symptoms.

Pericranial injection of EMG guided BTX-A, 100U, was found to be a safe treatment that significantly reduced migraine frequency, duration, migraine severity, and reduced associated symptoms.